Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
42.7 USD | +0.55% | +1.59% | +0.87% |
Apr. 18 | Sector Update: Health Care Stocks Mixed Pre-Bell Thursday | MT |
Apr. 18 | Cerevel Therapeutics' Potential Parkinson's Treatment Meets Primary Endpoint in Phase 3 Study | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.87% | 7.71B | |
-2.65% | 103B | |
+1.58% | 95.28B | |
+1.46% | 22.15B | |
-15.56% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-12.96% | 16.05B | |
+5.18% | 13.68B | |
+33.60% | 12.17B |
- Stock Market
- Equities
- CERE Stock
- News Cerevel Therapeutics Holdings, Inc.
- Morgan Stanley Adjusts Price Target on Cerevel Therapeutics to $42 From $46, Maintains Overweight Rating